EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan

Maya Suzuki iD, Yuhki Koga, Terumi Kawasaki, Tamaki Ueda iD, Shunsuke Yamamoto iD, Hironori Goto iD, Junji Kishimoto, Eiko Ishida, Koji Todaka, Koh-Hei Sonoda, Yoshinao Oda, Yoshimoto Koji und 2 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Maya Suzuki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics. Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Off-Label Use, Brain Neoplasms, Glioma. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programs allowing access to investigational drugs and off‐label drug use for serious diseases have often been applied to pediatric cancers. A clinical study conducted under the Japanese “Patient‐Proposed Healthcare Services” evaluated the efficacy and safety of dabrafenib plus trametinib in children with BRAF V600 mutant glioma (jRCTs071210071). This study successfully provided unapproved and off‐label medications to four enrolled patients, two with low‐grade glioma and two with high‐grade glioma (median age: 10.5 years), until regulatory approval. The timeframe and data collection from such access programs need to be optimized for pediatric patients in accordance with the healthcare system of each nation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafOff-Label UseBrain NeoplasmsGliomaMutationAntineoplastic Combined Chemotherapy ProtocolsHealth Services AccessibilityHumansChildOximesJapanMaleFemalePyridonesAdolescentImidazolesPyrimidinonesChild, PreschoolPrognosis

Stichwörter der Autor:innen

BRAF V600E‐mutated gliomaaccess programdabrafenibpatient‐proposed healthcare servicestrametinib

Substanzen

Proto-Oncogene Proteins B-rafdabrafenibOximesBRAF protein, humantrametinibPyridonesImidazolesPyrimidinones

Autor:innen und Institutionen

  • Department of Pediatrics. Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Pediatrics, National Hospital Organization (NHO) Kyushu Cancer Center, Fukuoka, Japan.
  • Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Maya Suzuki, Tamaki Ueda, Shunsuke Yamamoto, Hironori Goto

Zitieren

APA

Suzuki, M., Koga, Y., Kawasaki, T., Ueda, T., Yamamoto, S., Goto, H., Kishimoto, J., Ishida, E., Todaka, K., Sonoda, K. H., Oda, Y., Koji, Y., Sakai, Y., & Ohga, S. (2025). Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31510

Vancouver

Suzuki M, Koga Y, Kawasaki T, Ueda T, Yamamoto S, Goto H, et al. Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31510

BibTeX
@article{Suzuki2025,
  author = {Suzuki, Maya and Koga, Yuhki and Kawasaki, Terumi and Ueda, Tamaki and Yamamoto, Shunsuke and Goto, Hironori and Kishimoto, Junji and Ishida, Eiko and Todaka, Koji and Sonoda, Koh-Hei and Oda, Yoshinao and Koji, Yoshimoto and Sakai, Yasunari and Ohga, Shouichi},
  title = {Access Program for Unapproved and Off‐Label Drug Use in Pediatric BRAF V600E‐Mutated Brain Tumors in Japan},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31510}
}
Kostenlos starten →